Eton Pharmaceuticals, Inc. (ETON) Research

Eton Pharmaceuticals, Inc. functions as a specialized pharmaceutical enterprise, primarily focused on the invention and market introduction of medical treatments for rare diseases. Its current product lineup features Biorphen and Rezipres, both phenylephrine injections designed to counter significant hypotension arising from vasodilation during anesthesia. The company also offers Carglumic Acid, a treatment for acute and chronic hyperammonemia linked to N-acetylglutamate Synthase deficiency. Further marketed solutions include Alkindi Sprinkle, which serves as a replacement therapy for adrenocortical insufficiency in children younger than 17; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, an ophthalmic product for allergic conjunctivitis that contains no preservatives. Beyond its existing portfolio, Eton is actively developing various pipeline assets. These encompass oral suspensions of Zonisamide and Lamotrigine, both aimed at addressing partial on-set seizures, alongside a cysteine injection, a dehydrated alcohol injection, and the Zeneo hydrocortisone autoinjector. This company was established in 2017 and is headquartered in Deer Park, Illinois.

Open Eton Pharmaceuticals, Inc. (ETON) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.